[6]-gingerol: a novel AT₁ antagonist for the treatment of cardiovascular disease

Planta Med. 2013 Mar;79(5):322-6. doi: 10.1055/s-0032-1328262. Epub 2013 Mar 11.


Considering the prevalence of cardiovascular disease in public health and the limited validated therapeutic options, this study aimed to find novel compounds targeting the angiotensin II type 1 receptor, accepted as a therapeutic target in cardiovascular disease. A small library consisting of 89 compounds from 39 Chinese herbs was profiled using a cell-based calcium mobilization assay which was developed and characterized for high-throughput screening. [6]-Gingerol derived from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC50 value of 8.173 µM. The hit was further tested by a specificity assay indicating that it had no antagonistic effects on other evaluated GPCRs, such as endothelin receptors. The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 2 Receptor Blockers / analysis*
  • Cardiovascular Diseases / drug therapy
  • Catechols / pharmacology*
  • Catechols / therapeutic use
  • Drug Evaluation, Preclinical
  • Fatty Alcohols / pharmacology*
  • Fatty Alcohols / therapeutic use
  • HEK293 Cells
  • High-Throughput Screening Assays*
  • Humans
  • Plants, Medicinal / chemistry*
  • Zingiber officinale / chemistry


  • Angiotensin II Type 2 Receptor Blockers
  • Catechols
  • Fatty Alcohols
  • gingerol